[go: up one dir, main page]

PE20091727A1 - Agentes terapeuticos antivirales - Google Patents

Agentes terapeuticos antivirales

Info

Publication number
PE20091727A1
PE20091727A1 PE2009000334A PE2009000334A PE20091727A1 PE 20091727 A1 PE20091727 A1 PE 20091727A1 PE 2009000334 A PE2009000334 A PE 2009000334A PE 2009000334 A PE2009000334 A PE 2009000334A PE 20091727 A1 PE20091727 A1 PE 20091727A1
Authority
PE
Peru
Prior art keywords
oxo
alkyl
therapeutic agents
treatment
antiviral therapeutic
Prior art date
Application number
PE2009000334A
Other languages
English (en)
Inventor
Yarlagadda S Babu
Pooran Chand
Pravin L Kotian
Minwan Wu
V Satish Kumar
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of PE20091727A1 publication Critical patent/PE20091727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T10/00—Road transport of goods or passengers
    • Y02T10/10—Internal combustion engine [ICE] based vehicles
    • Y02T10/30—Use of alternative fuels, e.g. biofuels

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE B ES UN ANILLO CARBOCICLICO O HETEROCICLICO DE 5, 6, 7 U 8 ELEMENTOS QUE COMPRENDE UNO O MAS ENLACES DOBLES Y QUE ESTA OPCIONALMENTE SUSTITUIDO CON OXO, Br, CN, ENTRE OTROS; R1 ES H, F, NraRb, ENTRE OTROS; Ra Y Rb SON H, ALQUILO C1-C6, ALQUINILO C2-C10, ENTRE OTROS; R2 ES UN GRUPO NUCLEOSIDO DE AZUCAR TAL COMO RIBOSA, ARABINOSA, 2,3-DESOXIRIBOSA, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (88e), (93f), ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE POLIMERASAS VIRALES DEL ADN Y EL ARN Y SON UTILES PARA EL TRAMIENTO DE INFECCIONES VIRALES TALES COMO HCV, HIV Y HBV, O PARA EL TRATAMIENTO DEL CANCER
PE2009000334A 2008-03-05 2009-03-05 Agentes terapeuticos antivirales PE20091727A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3405308P 2008-03-05 2008-03-05
US7937008P 2008-07-09 2008-07-09

Publications (1)

Publication Number Publication Date
PE20091727A1 true PE20091727A1 (es) 2009-12-04

Family

ID=41054287

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000334A PE20091727A1 (es) 2008-03-05 2009-03-05 Agentes terapeuticos antivirales

Country Status (16)

Country Link
US (2) US7994139B2 (es)
EP (1) EP2265275A2 (es)
JP (1) JP2011525171A (es)
KR (1) KR20100137494A (es)
CN (1) CN102834513A (es)
AR (1) AR071745A1 (es)
AU (1) AU2009221770A1 (es)
BR (1) BRPI0910388A2 (es)
CA (1) CA2717173A1 (es)
EA (1) EA201070988A1 (es)
IL (1) IL207826A0 (es)
MX (1) MX2010009646A (es)
NZ (1) NZ588179A (es)
PE (1) PE20091727A1 (es)
TW (1) TW200942243A (es)
WO (1) WO2009111653A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535345A1 (en) * 2007-01-12 2012-12-19 BioCryst Pharmaceuticals, Inc. Anticancer nucleoside analogs
US8242085B2 (en) * 2007-05-10 2012-08-14 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer
US20090247750A1 (en) * 2008-03-28 2009-10-01 Biocryst Pharmaceuticals, Inc. Process for preparing nucleoside analogs
EA020659B1 (ru) 2008-04-23 2014-12-30 Джилид Сайэнс, Инк. 1'-замещённые карбануклеозидные аналоги для противовирусной терапии
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
CN102596979B (zh) 2009-09-21 2014-12-10 吉里德科学公司 用于制备1’-取代碳核苷类似物的方法和中间体
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
ES2524398T3 (es) 2010-07-19 2014-12-09 Gilead Sciences, Inc. Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros
EA025252B1 (ru) 2010-07-22 2016-12-30 Гайлид Сайэнсиз, Инк. Способы и соединения для лечения вирусных инфекций paramyxoviridae
CA2813783C (en) 2010-10-15 2019-01-22 Shanta Bantia Methods and compositions for inhibition of polymerase
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
US8906929B2 (en) * 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2970297A1 (en) * 2013-03-14 2016-01-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN104946646B (zh) * 2014-03-25 2020-03-31 中国医学科学院基础医学研究所 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
GEP20237502B (en) 2015-03-06 2023-04-25 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
MA52371A (fr) 2015-09-16 2021-09-22 Gilead Sciences Inc Méthodes de traitement d'infections dues aux coronaviridae
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
MA43812A (fr) 2016-03-06 2018-11-28 Biocryst Pharm Inc Procédés et compositions pour le traitement d'une infection par le virus zika
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EA202190602A3 (ru) 2016-09-07 2021-11-30 Атеа Фармасьютикалс, Инк. 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
GEP20237457B (en) 2017-02-01 2023-01-10 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for treatment of hepatitis c virus
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
CN115403626A (zh) 2017-05-01 2022-11-29 吉利德科学公司 新结晶形式
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
WO2020151682A1 (zh) * 2019-01-23 2020-07-30 成都先导药物开发股份有限公司 一种大环类免疫调节剂
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
JP7429799B2 (ja) 2020-02-18 2024-02-08 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
TWI890963B (zh) 2020-03-12 2025-07-21 美商基利科學股份有限公司 1'-氰基核苷之製備方法
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
KR102911165B1 (ko) 2020-06-24 2026-01-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오시드 유사체 및 이의 용도
SI4204421T1 (sl) 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
KR20240022574A (ko) 2021-06-17 2024-02-20 아테아 파마슈티컬즈, 인크. 유리한 항-hcv 조합 요법
KR20240049311A (ko) 2021-08-18 2024-04-16 길리애드 사이언시즈, 인코포레이티드 인지질 화합물 및 이의 제조 및 사용 방법
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012508A3 (cs) 1999-01-13 2002-02-13 Genentech, Inc. Inhibitory serinové proteázy
JP2002279640A (ja) 2001-03-21 2002-09-27 Ricoh Co Ltd ウォブル検出回路とその装置
PL1628685T3 (pl) 2003-04-25 2011-05-31 Gilead Sciences Inc Przeciwwirusowe analogi fosfonianowe
CA2537114C (en) 2003-08-27 2012-10-02 Biota, Inc. Tricyclic nucleosides or nucleotides as therapeutic agents
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN101166750A (zh) 2004-10-29 2008-04-23 拜奥克里斯特制药公司 治疗用呋喃并嘧啶类化合物和噻吩并嘧啶类化合物
AU2006218704A1 (en) 2005-02-28 2006-09-08 Genelabs Technologies, Inc. Tricyclic-nucleoside prodrugs for treating viral infections
US7842672B2 (en) * 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
EP2535345A1 (en) 2007-01-12 2012-12-19 BioCryst Pharmaceuticals, Inc. Anticancer nucleoside analogs
US8242085B2 (en) 2007-05-10 2012-08-14 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer

Also Published As

Publication number Publication date
US20120142617A1 (en) 2012-06-07
CA2717173A1 (en) 2009-09-11
EA201070988A1 (ru) 2011-12-30
US7994139B2 (en) 2011-08-09
WO2009111653A2 (en) 2009-09-11
IL207826A0 (en) 2010-12-30
MX2010009646A (es) 2010-09-28
JP2011525171A (ja) 2011-09-15
CN102834513A (zh) 2012-12-19
NZ588179A (en) 2012-09-28
WO2009111653A3 (en) 2011-09-22
KR20100137494A (ko) 2010-12-30
AU2009221770A1 (en) 2009-09-11
BRPI0910388A2 (pt) 2019-06-11
TW200942243A (en) 2009-10-16
US20090227524A1 (en) 2009-09-10
EP2265275A2 (en) 2010-12-29
AR071745A1 (es) 2010-07-14

Similar Documents

Publication Publication Date Title
PE20091727A1 (es) Agentes terapeuticos antivirales
MX2013003938A (es) Metodos y composiciones para inhibicion de polimerasa.
UY31476A1 (es) Nucleosidos 2' , 4' -sustituidos como agentes antivirales
PE20210668A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
PE20191552A1 (es) Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerizacion de fijacion a nucleotidos p3 (nlrp3)
JP2018088924A5 (es)
PE20120257A1 (es) Analogos carba-nucleosidicos para tratamiento antiviral
GT200500221A (es) Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan.
PE20151318A1 (es) Analogos de 2'-cloro nucleosido para infeccion por vhc
CL2011001364A1 (es) Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).
CL2013003053A1 (es) Compuesto que comprende un oligonucleotido modificado que consiste en de 10 a 30 nucleósidos unidos y definidos por un grupo de secuencias específicas; composicion que comprende dicho compuesto; uso para tratar enfermedades relacionadas con el virus de la hepatitis b (vhb).
UY33097A (es) DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS
PE20160658A1 (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos
CL2008000902A1 (es) Ester isopropilo del acido (s)-2-{[(2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidro-2h-pirimidin-1-il)-4-fluoro-3-hidroxi-4-metil-tetrahidro-furan-2-il-metoxi]-fenoxi-fosforilamino}-propionico; proceso de preparacion, composicion farmaceutica y su uso para tratar hepatitis c, virus del west nile, virus de fiebre amarilla, virus del dengue, rinovirus, virus del polio.
PE20050462A1 (es) COMPUESTOS DE 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINAS COMO INHIBIDORES DE LA FOSFODIESTERASA TIPO 5 (PDE-5)
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
AR056850A1 (es) MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA
CL2017001769A1 (es) Compuestos derivados de nucleosidos, nucleotidos y análogos de los mismos; composición farmacéutica que los comprende; útiles en el tratamiento de la hepatitis c (divisional de la solicitud 1699-2015).
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
PE20091458A1 (es) Compuestos heterociclicos antiviricos
EA201170915A1 (ru) Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций
ECSP10010210A (es) Compuestos nucleósidos antivirales
AR089650A1 (es) Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
CO6321235A2 (es) Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral
MX371440B (es) Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas.

Legal Events

Date Code Title Description
FC Refusal